(NASDAQ: ANNX) Annexon's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Annexon's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast ANNX's revenue for 2025 to be $3,016,756,951, with the lowest ANNX revenue forecast at $1,069,503,807, and the highest ANNX revenue forecast at $4,964,010,095. On average, 3 Wall Street analysts forecast ANNX's revenue for 2026 to be $6,656,760,944, with the lowest ANNX revenue forecast at $1,530,434,741, and the highest ANNX revenue forecast at $12,904,265,634.
In 2027, ANNX is forecast to generate $18,960,285,930 in revenue, with the lowest revenue forecast at $18,960,285,930 and the highest revenue forecast at $18,960,285,930.